Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

doi:10.1182/blood-2008-06-163246

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

Blood - 5 Feb 2009

Jiang Ying, Dunbar Andrew, Gondek Lukasz P, Mohan Sanjay, Rataul Manjot, O'Keefe Christine, Sekeres Mikkael, Saunthararajah Yogen, Maciejewski Jaroslaw P

Abstract excerpt

Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an intermediate disease stage before progression to acute myeloid leukemia (AML). As such, study of MDS/AML can provide insight into the mechanisms of neoplastic evolution. In 184 patients with MDS and AML, DNA methylation microarray and high-density single nucleotide polymorphism array (SNP-A) karyotyping were used to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to CpG Islands

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Frizzled Receptors

Share to Karyotyping

Share to Leukemia, Myeloid, Acute

Share to Microarray Analysis

Share to Myelodysplastic Syndromes

Share to Receptors, G-Protein-Coupled

Source

Open in PubMed Open full text

Identifiers

PMID: 18832655
DOI: 10.1182/blood-2008-06-163246
PMCID: PMC2637194

Genes

FZD9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.